The ARMOUR Study: Anti‐VEGF in Neovascular AMD—Our Understanding in a Real‐World Indian Setting. Issue 6 (November 2017)

• Record Type: Journal Article
• Authors: Jain, Nimesh; Yadav, Naresh Kumar; Jayadev, Chaitra; Srinivasan, Priya; Mohan, Ashwin; Shetty, Bhujang K.
• Is Part Of: Asia-Pacific journal of ophthalmology. Volume 6:Issue 6(2017)
• Publication Date: 2017-11
• Subjects: neovascular age related macular degeneration -- pro re nata -- anti‐vascular endothelial growth factor -- loading dose -- real world; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; Periodicals; 617.7005
• DOI: 10.22608/APO.2017125
• Languages: English
• ISSNs: 0129-1653

Abstract

Abstract : Purpose: : The aim of our study was to share our experience with anti‐vascular endothelial growth factor (anti‐VEGF) injections in the treatment of neovascular age‐related macular degeneration (nAMD) in a realworld setting. Design: : A retrospective, observational study. Methods: : Patients of Indian origin with nAMD receiving anti‐VEGF with a minimum follow‐up of 12 months were enrolled in this study. In group 1, patients were treated on a pro re nata (PRN) basis; in group 2, patients received a loading dose (3 injections) and were then treated on a PRN basis. Main outcome measures were mean change in corrected distance visual acuity (CDVA) and central subfield thickness (CSFT) from baseline to months 3 and 12. Results: : Overall, we observed that 77.31% (92/119 eyes) of patients either maintained or had improved visual acuity at 12 months' follow‐up. Similar visual outcome was observed in both groups. The average number of injections given in group 1 was 4.98 and in group 2 was 3.7. CDVA at 12 months was significantly correlated with type of drug molecule, CSFT at 3 and 12 months, baseline visual acuity, and CDVA at 3 months. Conclusions: : PRN treatment with significantly fewer injections achieved similar anatomical and functional outcomes when compared with the loading dose group. The results of this study need to be validated with a larger study group and a longer follow‐up. This real‐world observation shows that an individualized PRN approach without loading dose can be considered in the treatment of nAMD.